LevyCountyRAIsPEm Resource

From: Brian Anderson
Sent: Tuesday, March 03, 2009 1:55 PM
To: LevyCountyRAIsPEm Resource
Subject: REQUEST FOR ADDITIONAL INFORMATION LETTER NO. 015 RELATED TO SRP SECTION 11.3 FOR THE LEVY COUNTY UNITS 1 AND 2 COMBINED LICENSE APPLICATION
Attachments: LNP-RAI-LTR-015.doc

Importance: High

Hearing Identifier: Levy_County_COL_eRAIs
Email Number: 16

Mail Envelope Properties (CB87FC66F95637428C5E0D066E756B6FABAE160BD5)

Subject: REQUEST FOR ADDITIONAL INFORMATION LETTER NO. 015 RELATED TO SRP SECTION 11.3 FOR THE LEVY COUNTY UNITS 1 AND 2 COMBINED LICENSE APPLICATION
Sent Date: 3/3/2009 1:54:53 PM
Received Date: 3/3/2009 1:54:54 PM
From: Brian Anderson

Created By: Brian.Anderson@nrc.gov

Recipients:
"LevyCountyRAIsPEm Resource" <LevyCountyRAIsPEm.Resource@nrc.gov>
Tracking Status: None

Post Office: HQCLSTR01.nrc.gov

Files	**Size**	**Date & Time**
MESSAGE	3	3/3/2009 1:54:54 PM
LNP-RAI-LTR-015.doc	53242	

Options
Priority: High
Return Notification: No
Reply Requested: No
Sensitivity: Normal
Expiration Date:
Recipients Received:

March 3, 2009

Mr. Garry Miller
General Manager, Nuclear Plant Development
Progress Energy Florida, Inc.
PO Box 1551
411 Fayetteville Street Mall
Raleigh, NC 27602

SUBJECT: REQUEST FOR ADDITIONAL INFORMATION LETTER NO. 015 RELATED TO SRP SECTION 11.3 FOR THE LEVY COUNTY NUCLEAR PLANT, UNITS 1 and 2 COMBINED LICENSE APPLICATION

Dear Mr. Miller:

By letter dated July 28, 2008, as supplemented by a letter dated September 12, 2008, Progress Energy Florida, Inc. submitted its application to the U. S. Nuclear Regulatory Commission (NRC) for a combined license (COL) for two AP1000 advanced passive pressurized water reactors pursuant to 10 CFR Part 52. The NRC staff is performing a detailed review of this application to enable the staff to reach a conclusion on the safety of the proposed application.

The NRC staff has identified that additional information is needed to continue portions of the review. The staff's request for additional information (RAI) is contained in the enclosure to this letter.

To support the review schedule, you are requested to respond within 30 days of the date of this letter. If changes are needed to the final safety analysis report, the staff requests that the RAI response include the proposed wording changes.

If you have any questions or comments concerning this matter, you may contact me at 301-415-9967.

Sincerely,

/**RA**/

Brian C. Anderson, Lead Project Manager
AP1000 Projects Branch 1
Division of New Reactor Licensing
Office of New Reactors

Docket Nos. 52-029
52-030

eRAI Tracking No. 2152

Enclosure:
Request for Additional Information

If you have any questions or comments concerning this matter, you may contact me at 301-415-9967.

Sincerely,

/**RA**/

Brian C. Anderson, Lead Project Manager
AP1000 Projects Branch 1
Division of New Reactor Licensing
Office of New Reactors

Docket Nos. 52-029
52-030

eRAI Tracking No. 2152

Enclosure:
Request for Additional Information

Distribution:

Public	SCoffin	TSimms	SSchaffer
RidsNroDnrlNwe1	JSebrosky	SGoetz	TFrye
RidsNroLAKGoldstein	BHughes	SHaggerty	
RidsOgcMailCenter	MComar	JMartin	
RidsAcrsAcnw_MailCenter	CAraguas	SBrock	
RidsRgn2MailCenter	RJoshi	BAnderson	

NRO-002

OFFICE	CHPB/BC	NWE1/PM	OGC	NWE1/L-PM
NAME	TFrye *	RJoshi *	JMartin*	BAnderson*
DATE	02/09/09	02/09/09	02/13/09	03/03/09

*Approval captured electronically in the electronic RAI system.

OFFICIAL RECORD COPY

Request for Additional Information
Levy County, Units 1 and 2
Progress Energy Florida, Inc.
Docket No. 52-029 and 52-030
SRP Section: 11.03 - Gaseous Waste Management System
Application Section: FSAR Section 11.3

QUESTIONS for Health Physics Branch (CHPB)

11.03-1

Please provide detailed information to enable the staff to validate and verify the estimated doses in FSAR section 11.3.3.4 with respect to the dose objectives of Appendix I to 10 CFR Part 50 and the dose limits in 10 CFR 20.1301(e); please revise the FSAR to include this information, or justify its exclusion. The information should include the following:

• a complete description of how the applicant derived all the values listed in Table 11.3-201, including all assumptions made

• citations to any reference material used (for documents not publicly available please provide a copy for staff's use)

• detailed breakdown of individual doses by pathway and organ

• detailed breakdown of population doses by pathway and organ